Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.36 (
hyaluronidase
)
4,606
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Numerous cancer cells, when exposed to transforming growth factor beta (TGF-beta), become resistant to tumor necrosis factor (TNF) cytotoxicity. Pretreatment of L929 fibroblasts, for example, with TGF-beta isoforms (
beta 1
, beta 2 and beta 3) for at least 0.5-1 h results in resistance to TNF killing. TGF-
beta 1
mediates the following sequential events in L929 cells: i) rapid induction of protein tyrosine-phosphorylation (< 30 min), ii) stimulation of protective protein synthesis and acquisition of TNF resistance (approximately 0.5-1 h), and iii) suppression of I kappa B-alpha expression (1-2 h). Two protective proteins induced by TGF-
beta 1
are a 46 kDa extracellular matrix TNF-resistance triggering (TRT) protein and a putative transmembrane anti-apoptotic adhesion protein TIF2 (containing and RGD motif in the extracellular region). Both proteins enable L929 cells to resist TNF killing. Notably, testicular
hyaluronidase
increases TNF sensitivity in several types of cancer cells, counteracts TGF-beta-mediated TNF-resistance, and suppresses TGF-
beta 1
gene expression in L929 cells in a serum-dependent manner. Moreover,
hyaluronidase
antagonizes TGF-beta-mediated inhibition of epithelial cell growth. Both TGF-beta and
hyaluronidase
are essential for the progression and invasiveness of breast, prostate and other cancers. Conceivably, a stage-dependent expression, as well as a balanced production, of these proteins is essential for cancer development and self protection against TNF cytotoxicity.
...
PMID:Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). 985 Jul 32
The action of
hyaluronidase
on oligosaccharides from hyaluronan is complicated due to branched reaction paths containing hydrolysis, transglycosylation and condensation. The unit component of hyaluronan is a disaccharide, namely GlcA-(
beta 1
-->3)-GlcNAc where GlcA and GlcNAc are d-glucuronic acid and d-N-acetylglucosamine respectively. Hyaluronan is the linear polymer formed by these disaccharide units, linked together with
beta 1
-->4 glycosidic bonds. Bovine testicular
hyaluronidase
acts only at
beta 1
-->4 glycosidic bonds of hyaluronan. The progress of product distribution from short oligosaccharides was simulated with the Monte Carlo method using the probabilistic model. The model consists only of a single enzyme molecule and a finite number of substrate and water molecules. The simulation is based on a simple reaction scheme and proceeds via an algorithm with minimum adjustable parameters generating random numbers and probabilities. The experimental data for bovine testicular
hyaluronidase
using [GlcA-(
beta 1
-->3)-GlcNAc](4) as the starting substrate were quantitatively simulated with only three adjustable parameters. The simulated data for [GlcA-(
beta 1
-->3)-GlcNAc](3) and [GlcA-(
beta 1
-->3)-GlcNAc](5) as the starting substrates agreed semi-quantitatively with experimental data using the same parameters. The mechanism of the
hyaluronidase
reaction is a combination of branched probabilistic cycles. The condensation reaction is much weaker than the transglycosylation reaction but contributes to product distribution at the final stage of the reaction, preventing complete hydrolysis of the substrates.
...
PMID:Monte Carlo simulation of hyaluronidase reaction involving hydrolysis, transglycosylation and condensation. 1196 43
In the previous study, we have found that the endo-beta-xylosidase from Patinopecten had the attachment activities of glycosaminoglycan (GAG) chains to peptide. As artificial carrier substrates for this reaction, synthesis of various GAG chains having the linkage region tetrasaccharide, GlcA
beta 1
-3Gal
beta 1
-3Gal
beta 1
-4Xyl, between GAG chain and core protein of proteoglycan was investigated. Hyaluronic acid (HA), chondroitin (Ch), chondroitin 4-sulfate (Ch4S), chondroitin 6-sulfate (Ch6S), and desulfated dermatan sulfate (desulfated DS) as donors and the 4-metylumbelliferone (MU)-labeled hexasaccharide having the linkage region tetrasaccharide at its reducing terminals (MU-hexasaccharide) as an acceptor were subjected to a transglycosylation reaction of testicular
hyaluronidase
. The products were analyzed by high-performance liquid chromatography and enzyme digestion, and the results indicated that HA, Ch, Ch4S, Ch6S, and desulfated DS chains elongated by the addition of disaccharide units to the nonreducing terminal of MU-hexasaccharide. It was possible to custom-synthesize various GAG chains having the linkage region tetrasaccharide as carrier substrates for enzymatic attachment of GAG chains to peptide.
...
PMID:Carriers for enzymatic attachment of glycosaminoglycan chains to peptide. 1205 87
Hyaluronidase, ubiquitous enzyme in snake venoms, known originally as "spreading factor", has not been well studied. The present study describes the purification and characterization of
hyaluronidase
from Indian cobra (Naja naja) venom and provides systematic evaluation of the spreading property of the enzyme. Hyaluronidase (NNH1) has been purified through gel permeation and ion exchange chromatography. The molecular mass was found to be 70.406 kDa by MALDI-TOF mass spectrometry and with the (p)i pI of 9.2. The amino acid sequence of the N-terminus was found to be NEQSTHGAYV. The enzyme shows absolute specificity for hyaluronan and belongs to the group of neutral active enzymes. Tetrasaccharides are the final product of hyaluronan digestion. The enzyme cleaves
beta 1
,4-glycosidic linkage and belongs to a group of endo-beta-N-acetyl hexosaminidases. Hyaluronidase indirectly potentiates the myotoxicity of VRV-PL-VIII, a phospholipolytic myotoxin, and also the hemorrhagic potency of a hemorrhagic complex-I. Localization of hyaluronan in human skin section and selective degradation by venom
hyaluronidase
(NNH1) corroborate the plausible in vivo degradation of hyaluronan in the extracellular matrix (ECM) resulting in easy dissemination of VRV-PL-VIII myotoxin and hemorrhagic complex-I.
...
PMID:Isolation and characterization of hyaluronidase a "spreading factor" from Indian cobra (Naja naja) venom. 1513 34
Various pharmacologic vitreolysis agents, including
hyaluronidase
, urea, plasmin, dispase, tissue plasminogen activator and chondroitinase have been tested. Pharmacologic vitreolysis can avoid the complications of surgery such as cataract, endophthalmitis, retinal hemorrhage, tear or detachment, and anesthesia related complications. Hyaluronan is a major macromolecule of vitreous. It is a long, unbranched polymer of repeating disaccharide (glucuronic acid beta (1,3)-N-acetylglucosamine) moieties linked by
beta 1
-4 bonds. Hyaluronan is covalently linked to a protein core, to form a proteoglycan. It plays a pivotal role in stabilizing the vitreous gel. Hyaluronidase cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, other acid mucopolysaccharides of the connective tissue. Dissolution of the hyaluronic acid and collagen complex results in decreased viscosity of the extracellular matrix. This in turn increases the diffusion rate of erythrocytes and exudates along with phagocytes through the vitreous and facilitates red blood cell lysis and phagocytosis.
...
PMID:Hyaluronidase for pharmacologic vitreolysis. 1949 48
<< Previous
1
2